Waldencast plc strengthens balance sheet position with the announcement of a trademark sale for Japan and refinancing of its credit facilitiesNEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (
NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced that it had sold its rights to the “Obagi” trademark in Japan to Rohto Pharmaceutical Co., Ltd. (“Rohto”) for USD $82.5 million.
Waldencast plc Provides Information Regarding Upcoming Earnings Release DatesFirst Half Fiscal 2025 Results and Q3 2025 Financial Results Expected to be Reported on November 24, 2025
Obagi Medical Launches Nu-Cil® BioStim™ Scalp SerumA Next-Generation, Redensifying Scalp Serum Clinically Proven to Promote Fuller, Denser-Looking Hair*
Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical BrandU.S. Launch Planned in 2026 and Positions Obagi Medical as a Leading Dermatological Megabrand at the Convergence of Integrated Skincare and Aesthetics While Doubling its Addressable Market
Waldencast Announces Strong Progress on Business Priorities for H1 2025 and Initiatives to Drive TransformationObagi Medical delivers H1 2025 double-digit growth in its Core Strategic Channels. Novaestiq Acquisition Doubles the Brand’s Addressable Market in the U.S.
